Example of Endocrine Pathology format
Recent searches

Example of Endocrine Pathology format Example of Endocrine Pathology format Example of Endocrine Pathology format Example of Endocrine Pathology format Example of Endocrine Pathology format Example of Endocrine Pathology format Example of Endocrine Pathology format Example of Endocrine Pathology format Example of Endocrine Pathology format Example of Endocrine Pathology format Example of Endocrine Pathology format Example of Endocrine Pathology format Example of Endocrine Pathology format Example of Endocrine Pathology format Example of Endocrine Pathology format Example of Endocrine Pathology format Example of Endocrine Pathology format Example of Endocrine Pathology format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
Look Inside
Example of Endocrine Pathology format Example of Endocrine Pathology format Example of Endocrine Pathology format Example of Endocrine Pathology format Example of Endocrine Pathology format Example of Endocrine Pathology format Example of Endocrine Pathology format Example of Endocrine Pathology format Example of Endocrine Pathology format Example of Endocrine Pathology format Example of Endocrine Pathology format Example of Endocrine Pathology format Example of Endocrine Pathology format Example of Endocrine Pathology format Example of Endocrine Pathology format Example of Endocrine Pathology format Example of Endocrine Pathology format Example of Endocrine Pathology format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
open access Open Access

Endocrine Pathology — Template for authors

Publisher: Springer
Categories Rank Trend in last 3 yrs
Pathology and Forensic Medicine #31 of 191 up up by 17 ranks
Endocrinology, Diabetes and Metabolism #56 of 219 up up by 41 ranks
Endocrinology #42 of 117 up up by 26 ranks
journal-quality-icon Journal quality:
High
calendar-icon Last 4 years overview: 185 Published Papers | 1072 Citations
indexed-in-icon Indexed in: Scopus
last-updated-icon Last updated: 14/07/2020
Related journals
Insights
General info
Top papers
Popular templates
Get started guide
Why choose from SciSpace
FAQ

Related Journals

open access Open Access

Springer

Quality:  
High
CiteRatio: 6.0
SJR: 1.141
SNIP: 1.158
open access Open Access
recommended Recommended

Springer

Quality:  
High
CiteRatio: 6.6
SJR: 1.078
SNIP: 1.275
open access Open Access

Springer

Quality:  
High
CiteRatio: 6.1
SJR: 1.034
SNIP: 1.318
open access Open Access
recommended Recommended

Elsevier

Quality:  
High
CiteRatio: 7.8
SJR: 1.955
SNIP: 1.488

Journal Performance & Insights

Impact Factor

CiteRatio

Determines the importance of a journal by taking a measure of frequency with which the average article in a journal has been cited in a particular year.

A measure of average citations received per peer-reviewed paper published in the journal.

3.168

6% from 2018

Impact factor for Endocrine Pathology from 2016 - 2019
Year Value
2019 3.168
2018 3.366
2017 2.541
2016 1.936
graph view Graph view
table view Table view

5.8

18% from 2019

CiteRatio for Endocrine Pathology from 2016 - 2020
Year Value
2020 5.8
2019 4.9
2018 4.1
2017 3.9
2016 3.0
graph view Graph view
table view Table view

insights Insights

  • Impact factor of this journal has decreased by 6% in last year.
  • This journal’s impact factor is in the top 10 percentile category.

insights Insights

  • CiteRatio of this journal has increased by 18% in last years.
  • This journal’s CiteRatio is in the top 10 percentile category.

SCImago Journal Rank (SJR)

Source Normalized Impact per Paper (SNIP)

Measures weighted citations received by the journal. Citation weighting depends on the categories and prestige of the citing journal.

Measures actual citations received relative to citations expected for the journal's category.

0.99

12% from 2019

SJR for Endocrine Pathology from 2016 - 2020
Year Value
2020 0.99
2019 0.886
2018 0.843
2017 0.734
2016 0.531
graph view Graph view
table view Table view

1.314

12% from 2019

SNIP for Endocrine Pathology from 2016 - 2020
Year Value
2020 1.314
2019 1.172
2018 0.905
2017 0.922
2016 0.782
graph view Graph view
table view Table view

insights Insights

  • SJR of this journal has increased by 12% in last years.
  • This journal’s SJR is in the top 10 percentile category.

insights Insights

  • SNIP of this journal has increased by 12% in last years.
  • This journal’s SNIP is in the top 10 percentile category.

Endocrine Pathology

Guideline source: View

All company, product and service names used in this website are for identification purposes only. All product names, trademarks and registered trademarks are property of their respective owners.

Use of these names, trademarks and brands does not imply endorsement or affiliation. Disclaimer Notice

Springer

Endocrine Pathology

Endocrine Pathology publishes original articles on clinical and basic aspects of endocrine disorders. Work with animals or in vitro techniques is acceptable if it is relevant to human normal or abnormal endocrinology. Manuscripts will be considered for publication in the form ...... Read More

Medicine

i
Last updated on
14 Jul 2020
i
ISSN
1046-3976
i
Impact Factor
Medium - 0.824
i
Open Access
No
i
Sherpa RoMEO Archiving Policy
Green faq
i
Plagiarism Check
Available via Turnitin
i
Endnote Style
Download Available
i
Bibliography Name
SPBASIC
i
Citation Type
Author Year
(Blonder et al, 1982)
i
Bibliography Example
Beenakker CWJ (2006) Specular andreev reflection in graphene. Phys Rev Lett 97(6):067,007, URL 10.1103/PhysRevLett.97.067007

Top papers written in this journal

Journal Article DOI: 10.1385/EP:13:1:03
RET/PTC rearrangement in thyroid tumors.
Yuri E. Nikiforov1
01 Jan 2002 - Endocrine Pathology

Abstract:

Rearrangement of the RET gene, also known as RET/PTC rearrangement, is the most common genetic alteration identified to date in thyroid papillary carcinomas. The prevalence of RET/PTC in papillary carcinomas shows significant geographic variation and is approx 35% in North America. RET/PTC is more common in tumors in children... Rearrangement of the RET gene, also known as RET/PTC rearrangement, is the most common genetic alteration identified to date in thyroid papillary carcinomas. The prevalence of RET/PTC in papillary carcinomas shows significant geographic variation and is approx 35% in North America. RET/PTC is more common in tumors in children and young adults, and in papillary carcinomas associated with radiation exposure. There are at least 10 different types of RET/PTC, all resulting from the fusion of the tyrosine kinase domain of RET to the 5′ portion of different genes. RET/PTC1 and RET/PTC3 are the most common types, accounting for >90% of all rearrangements. There is some evidence that different types of RET/PTC may be associated with distinct biologic properties of papillary carcinomas. RET/PTC1 tends to be more common in tumors with typical papillary growth and microcarcinomas and to have a more benign clinical course, whereas RET/PTC3 in some populations shows a strong correlation with the solid variant of papillary carcinoma and more aggressive tumor behavior. RET/PTC has recently been found in hyalinizing trabecular adenomas of the thyroid gland, providing molecular evidence in favor of this tumor to be a variant of papillary carcinoma. The occurrence of RET/PTC in Hashimoto thyroiditis and thyroid follicular adenomas and hyperplastic nodules reported in several studies has not been confirmed in other observations and remains controversial. read more read less

Topics:

RET/PTC Rearrangement (85%)85% related to the paper, Gene rearrangement (54%)54% related to the paper
425 Citations
Journal Article DOI: 10.1007/S12022-017-9498-Z
Overview of the 2017 WHO Classification of Pituitary Tumors
Ozgur Mete1, Ozgur Mete2, Ozgur Mete3, M. Beatriz S. Lopes4
01 Sep 2017 - Endocrine Pathology

Abstract:

This review focuses on discussing the main changes on the upcoming fourth edition of the WHO Classification of Tumors of the Pituitary Gland emphasizing histopathological and molecular genetics aspects of pituitary neuroendocrine (i.e., pituitary adenomas) and some of the non-neuroendocrine tumors involving the pituitary glan... This review focuses on discussing the main changes on the upcoming fourth edition of the WHO Classification of Tumors of the Pituitary Gland emphasizing histopathological and molecular genetics aspects of pituitary neuroendocrine (i.e., pituitary adenomas) and some of the non-neuroendocrine tumors involving the pituitary gland. Instead of a formal review, we introduced the highlights of the new WHO classification by answering select questions relevant to practising pathologists. The revised classification of pituitary adenomas, in addition to hormone immunohistochemistry, recognizes the role of other immunohistochemical markers including but not limited to pituitary transcription factors. Recognizing this novel approach, the fourth edition of the WHO classification has abandoned the concept of “a hormone-producing pituitary adenoma” and adopted a pituitary adenohypophyseal cell lineage designation of the adenomas with subsequent categorization of histological variants according to hormone content and specific histological and immunohistochemical features. This new classification does not require a routine ultrastructural examination of these tumors. The new definition of the Null cell adenoma requires the demonstration of immunonegativity for pituitary transcription factors and adenohypophyseal hormones Moreover, the term of atypical pituitary adenoma is no longer recommended. In addition to the accurate tumor subtyping, assessment of the tumor proliferative potential by mitotic count and Ki-67 index, and other clinical parameters such as tumor invasion, is strongly recommended in individual cases for consideration of clinically aggressive adenomas. This classification also recognizes some subtypes of pituitary neuroendocrine tumors as “high-risk pituitary adenomas” due to the clinical aggressive behavior; these include the sparsely granulated somatotroph adenoma, the lactotroph adenoma in men, the Crooke’s cell adenoma, the silent corticotroph adenoma, and the newly introduced plurihormonal Pit-1-positive adenoma (previously known as silent subtype III pituitary adenoma). An additional novel aspect of the new WHO classification was also the definition of the spectrum of thyroid transcription factor-1 expressing pituitary tumors of the posterior lobe as representing a morphological spectrum of a single nosological entity. These tumors include the pituicytoma, the spindle cell oncocytoma, the granular cell tumor of the neurohypophysis, and the sellar ependymoma. read more read less

Topics:

Pituitary tumors (72%)72% related to the paper, Pituicytoma (65%)65% related to the paper, Pituitary adenoma (65%)65% related to the paper, Adenoma (65%)65% related to the paper, Pituitary gland (57%)57% related to the paper
283 Citations
open accessOpen access Journal Article DOI: 10.1007/S12022-017-9484-5
Update on Adrenal Tumours in 2017 World Health Organization (WHO) of Endocrine Tumours.
Alfred King-Yin Lam1
06 May 2017 - Endocrine Pathology

Abstract:

The fourth edition of the World Health Organization (WHO) classification of endocrine tumours contains substantial new findings for the adrenal tumours. The tumours are presented in two chapters labelled as "Tumours of the adrenal cortex" and "Tumours of the adrenal medulla and extra-adrenal paraganglia." Tumours of the adren... The fourth edition of the World Health Organization (WHO) classification of endocrine tumours contains substantial new findings for the adrenal tumours. The tumours are presented in two chapters labelled as "Tumours of the adrenal cortex" and "Tumours of the adrenal medulla and extra-adrenal paraganglia." Tumours of the adrenal cortex are classified as cortical carcinoma, cortical adenoma, sex cord stromal tumours, adenomatoid tumour, mesenchymal and stromal tumours (myelolipoma and schwannoma), haematological tumours, and secondary tumours. Amongst them, schwannoma and haematological tumours are newly documented. The major updates in adrenal cortical lesions are noted in the genetics of the cortical carcinoma and cortical adenoma based on the data from The Cancer Genome Atlas (TCGA). Also, a system for differentiation of oncocytoma from oncocytic cortical carcinoma is adopted. Tumours of the adrenal medulla and extra-adrenal paraganglia comprise pheochromocytoma, paraganglioma (head and neck paraganglioma and sympathetic paraganglioma), neuroblastic tumours (neuroblastoma, nodular ganglioneuroblastoma, intermixed ganglioneuroblastoma, and ganglioneuroma), composite pheochromocytoma, and composite paraganglioma. In this group, neuroblastic tumours are newly included in the classification. The clinical features, histology, associated pathologies, genetics, and predictive factors of pheochromocytoma and paraganglioma are the main changes introduced in this chapter of WHO classification of endocrine tumours. The term "metastatic pheochromocytoma/paraganglioma" is used to replace "malignant pheochromocytoma/paraganglioma." Also, composite pheochromocytoma and composite paraganglioma are now documented in separate sections instead of one. Overall, the new classification incorporated new data on pathology, clinical behaviour, and genetics of the adrenal tumours that are important for current management of patients with these tumours. read more read less

Topics:

Sympathetic Paraganglioma (59%)59% related to the paper, Paraganglioma (58%)58% related to the paper, Adrenal Gland Neoplasm (55%)55% related to the paper, Pheochromocytoma (54%)54% related to the paper, Ganglioneuroblastoma (52%)52% related to the paper
View PDF
267 Citations
Journal Article DOI: 10.1007/s12022-022-09707-3
Overview of the 2022 WHO Classification of Thyroid Neoplasms
01 Mar 2022 - Endocrine Pathology

Topics:

Medicine (100%)100% related to the paper, Thyroid (80%)80% related to the paper, Adenoma (63%)63% related to the paper, Medicine (61%)61% related to the paper, Follicular cell (60%)60% related to the paper
214 Citations
Journal Article DOI: 10.1007/S12022-007-0023-7
Differential Expression of miRNAs in Papillary Thyroid Carcinoma Compared to Multinodular Goiter Using Formalin Fixed Paraffin Embedded Tissues
09 Aug 2007 - Endocrine Pathology

Abstract:

microRNAs (miRNAs) are approximately 22 nt RNAs that negatively regulate target gene expression. Their dysregulation has been implicated in the pathogenesis of a number of human cancers, including papillary thyroid carcinoma (PTC). Whereas previous studies using microarray technologies have largely relied on the ability to pr... microRNAs (miRNAs) are approximately 22 nt RNAs that negatively regulate target gene expression. Their dysregulation has been implicated in the pathogenesis of a number of human cancers, including papillary thyroid carcinoma (PTC). Whereas previous studies using microarray technologies have largely relied on the ability to procure fresh tissue at the time of surgery to characterize miRNA signatures in PTC, we exploited the ability to procure sufficient miRNA from formalin-fixed paraffin-embedded (FFPE) tissue to describe a series of miRNAs whose expression is dysregulated in PTC compared to benign proliferative multinodular goiter (MNG). We identified 13 miRNAs upregulated and 26 miRNAs downregulated in PTC versus MNG. These include miRNA-21, miRNA-31, miRNA-221, and miRNA-222. Their dysregulation was further validated by real time RT-PCR analysis in an independent set of FFPE tissues. Many of these have previously been described in fresh tissue studies as altered in PTC, confirming the utility of this approach. These results further highlight the applicability of miRNA expression patterns as potential markers of human cancer, and our results suggest that FFPE tissues are suitable resources for such miRNA expression analyses. The ability to utilize FFPE tissue in the molecular characterization of human malignancy will unlock a rich resource for future cancer studies. read more read less
208 Citations
Author Pic

SciSpace is a very innovative solution to the formatting problem and existing providers, such as Mendeley or Word did not really evolve in recent years.

- Andreas Frutiger, Researcher, ETH Zurich, Institute for Biomedical Engineering

Get MS-Word and LaTeX output to any Journal within seconds
1
Choose a template
Select a template from a library of 40,000+ templates
2
Import a MS-Word file or start fresh
It takes only few seconds to import
3
View and edit your final output
SciSpace will automatically format your output to meet journal guidelines
4
Submit directly or Download
Submit to journal directly or Download in PDF, MS Word or LaTeX

(Before submission check for plagiarism via Turnitin)

clock Less than 3 minutes

What to expect from SciSpace?

Speed and accuracy over MS Word

''

With SciSpace, you do not need a word template for Endocrine Pathology.

It automatically formats your research paper to Springer formatting guidelines and citation style.

You can download a submission ready research paper in pdf, LaTeX and docx formats.

Time comparison

Time taken to format a paper and Compliance with guidelines

Plagiarism Reports via Turnitin

SciSpace has partnered with Turnitin, the leading provider of Plagiarism Check software.

Using this service, researchers can compare submissions against more than 170 million scholarly articles, a database of 70+ billion current and archived web pages. How Turnitin Integration works?

Turnitin Stats
Publisher Logos

Freedom from formatting guidelines

One editor, 100K journal formats – world's largest collection of journal templates

With such a huge verified library, what you need is already there.

publisher-logos

Easy support from all your favorite tools

Endocrine Pathology format uses SPBASIC citation style.

Automatically format and order your citations and bibliography in a click.

SciSpace allows imports from all reference managers like Mendeley, Zotero, Endnote, Google Scholar etc.

Frequently asked questions

1. Can I write Endocrine Pathology in LaTeX?

Absolutely not! Our tool has been designed to help you focus on writing. You can write your entire paper as per the Endocrine Pathology guidelines and auto format it.

2. Do you follow the Endocrine Pathology guidelines?

Yes, the template is compliant with the Endocrine Pathology guidelines. Our experts at SciSpace ensure that. If there are any changes to the journal's guidelines, we'll change our algorithm accordingly.

3. Can I cite my article in multiple styles in Endocrine Pathology?

Of course! We support all the top citation styles, such as APA style, MLA style, Vancouver style, Harvard style, and Chicago style. For example, when you write your paper and hit autoformat, our system will automatically update your article as per the Endocrine Pathology citation style.

4. Can I use the Endocrine Pathology templates for free?

Sign up for our free trial, and you'll be able to use all our features for seven days. You'll see how helpful they are and how inexpensive they are compared to other options, Especially for Endocrine Pathology.

5. Can I use a manuscript in Endocrine Pathology that I have written in MS Word?

Yes. You can choose the right template, copy-paste the contents from the word document, and click on auto-format. Once you're done, you'll have a publish-ready paper Endocrine Pathology that you can download at the end.

6. How long does it usually take you to format my papers in Endocrine Pathology?

It only takes a matter of seconds to edit your manuscript. Besides that, our intuitive editor saves you from writing and formatting it in Endocrine Pathology.

7. Where can I find the template for the Endocrine Pathology?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per Endocrine Pathology's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

8. Can I reformat my paper to fit the Endocrine Pathology's guidelines?

Of course! You can do this using our intuitive editor. It's very easy. If you need help, our support team is always ready to assist you.

9. Endocrine Pathology an online tool or is there a desktop version?

SciSpace's Endocrine Pathology is currently available as an online tool. We're developing a desktop version, too. You can request (or upvote) any features that you think would be helpful for you and other researchers in the "feature request" section of your account once you've signed up with us.

10. I cannot find my template in your gallery. Can you create it for me like Endocrine Pathology?

Sure. You can request any template and we'll have it setup within a few days. You can find the request box in Journal Gallery on the right side bar under the heading, "Couldn't find the format you were looking for like Endocrine Pathology?”

11. What is the output that I would get after using Endocrine Pathology?

After writing your paper autoformatting in Endocrine Pathology, you can download it in multiple formats, viz., PDF, Docx, and LaTeX.

12. Is Endocrine Pathology's impact factor high enough that I should try publishing my article there?

To be honest, the answer is no. The impact factor is one of the many elements that determine the quality of a journal. Few of these factors include review board, rejection rates, frequency of inclusion in indexes, and Eigenfactor. You need to assess all these factors before you make your final call.

13. What is Sherpa RoMEO Archiving Policy for Endocrine Pathology?

SHERPA/RoMEO Database

We extracted this data from Sherpa Romeo to help researchers understand the access level of this journal in accordance with the Sherpa Romeo Archiving Policy for Endocrine Pathology. The table below indicates the level of access a journal has as per Sherpa Romeo's archiving policy.

RoMEO Colour Archiving policy
Green Can archive pre-print and post-print or publisher's version/PDF
Blue Can archive post-print (ie final draft post-refereeing) or publisher's version/PDF
Yellow Can archive pre-print (ie pre-refereeing)
White Archiving not formally supported
FYI:
  1. Pre-prints as being the version of the paper before peer review and
  2. Post-prints as being the version of the paper after peer-review, with revisions having been made.

14. What are the most common citation types In Endocrine Pathology?

The 5 most common citation types in order of usage for Endocrine Pathology are:.

S. No. Citation Style Type
1. Author Year
2. Numbered
3. Numbered (Superscripted)
4. Author Year (Cited Pages)
5. Footnote

15. How do I submit my article to the Endocrine Pathology?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per Endocrine Pathology's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

16. Can I download Endocrine Pathology in Endnote format?

Yes, SciSpace provides this functionality. After signing up, you would need to import your existing references from Word or Bib file to SciSpace. Then SciSpace would allow you to download your references in Endocrine Pathology Endnote style according to Elsevier guidelines.

Fast and reliable,
built for complaince.

Instant formatting to 100% publisher guidelines on - SciSpace.

Available only on desktops 🖥

No word template required

Typset automatically formats your research paper to Endocrine Pathology formatting guidelines and citation style.

Verifed journal formats

One editor, 100K journal formats.
With the largest collection of verified journal formats, what you need is already there.

Trusted by academicians

I spent hours with MS word for reformatting. It was frustrating - plain and simple. With SciSpace, I can draft my manuscripts and once it is finished I can just submit. In case, I have to submit to another journal it is really just a button click instead of an afternoon of reformatting.

Andreas Frutiger
Researcher & Ex MS Word user
Use this template